{"id":4193,"date":"2024-03-04T06:30:47","date_gmt":"2024-03-04T11:30:47","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2024-du-nanos\/"},"modified":"2026-09-24T00:05:52","modified_gmt":"2026-09-24T04:05:52","slug":"gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2024-du-nanos","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2024\/03\/04\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2024-du-nanos\/","title":{"rendered":"GenSight Biologics annonce des communications scientifiques sur LUMEVOQ\u00ae au Congr\u00e8s 2024 du NANOS"},"content":{"rendered":"\nParis, France, le lundi, 4 mars 2024, 7h30 CET<\/strong> \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui que de nouvelles donn\u00e9es et analyses scientifiques relatives \u00e0 la th\u00e9rapie g\u00e9nique LUMEVOQ\u00ae seront pr\u00e9sent\u00e9es lors du 50e Congr\u00e8s Annuel de la North American Neuro-Ophthalmology Society<\/em> (NANOS) qui se tient \u00e0 Honolulu, Hawa\u00ef Etats-Unis, du 2 au 7 mars 2024.\n\nDes leaders d\u2019opinion (KOLs<\/em>) dans le domaine de la Neuropathie Optique H\u00e9r\u00e9ditaire de Leber (NOHL) communiqueront des r\u00e9sultats r\u00e9cents concernant l’effet controlat\u00e9ral, partageront des donn\u00e9es en vie r\u00e9elle de LUMEVOQ\u00ae<\/sup>, et pr\u00e9senteront une analyse comparative entre l’histoire naturelle de la NOHL, l’id\u00e9b\u00e9none et LUMEVOQ\u00ae<\/sup>.\n\nPoster<\/u> : \u201cUnilateral injection of lenadogene nolparvovec gene therapy induces successful transfection of retinal ganglion cells in both eyes\u201d<\/em>\n
    \n \t
  • Pr\u00e9sent\u00e9 par : Alfredo A. Sadun, MD, PhD<\/strong>, Doheny Eye Centers-UCLA, Pasadena, Californie, Etats-Unis<\/li>\n \t
  • Date et heure : dimanche 3 mars 2024, de 12h00 \u00e0 13h00 <\/strong>HST<\/li>\n \t
  • Lieu : Lanai room<\/li>\n<\/ul>\nPoster<\/u> : \u201cIn the real-life setting, lenadogene nolparvovec gene therapy improves visual acuity in patients with MT-ND4 LHON<\/em>\u201d\n
      \n \t
    • Pr\u00e9sent\u00e9 par : Chiara La Morgia, MD<\/strong>, Universit\u00e9 de Bologne, Italie<\/li>\n \t
    • Date et heure : mardi 5 mars 2024, de 19h00 \u00e0 20h00 HST<\/strong><\/li>\n \t
    • Lieu : Lanai room<\/li>\n<\/ul>\nPoster<\/u> : \u201cLenadogene nolparvovec gene therapy improves visual recovery more than idebenone in m.11778G>A MT-ND4 LHON, and both treatments exceed the natural course of the disease<\/em>\u201d\n
        \n \t
      • Pr\u00e9sent\u00e9 par : Nancy J. Newman, MD<\/strong>, Emory University School of Medicine, Atlanta, Georgie, Etats-Unis<\/li>\n \t
      • Date et heure : mardi 5 mars 2024, de 20h00 \u00e0 21h30 <\/strong>HST<\/li>\n \t
      • Lieu : Lanai room<\/li>\n<\/ul>\nEn outre, Benson S. Chen, <\/strong>MBChB, MSc, FRACP<\/strong>, D\u00e9partement de Neurosciences Cliniques, Universit\u00e9 de Cambridge et Cambridge Eye Unit<\/em>, Addenbrooke\u2019s Hospital<\/em>, Royaume-Uni, pr\u00e9sentera des donn\u00e9es sur la qualit\u00e9 de vie des patients atteints de Neuropathie Optique H\u00e9r\u00e9ditaire de Leber (NOHL) lors d’une pr\u00e9sentation orale.\n\nPr\u00e9sentation orale<\/u> : \u201cVision-Related Quality of Life in LHON Patients Treated with Lenadogene Nolparvovec Gene Therapy: Analysis of the VFQ-25 Using Rasch Measurement Theory<\/em>\u201d\n
          \n \t
        • Session\u00a0: Scientific Platform Session III<\/li>\n \t
        • Date et heure : mardi 5 mars 2024, de <\/strong>11h15 \u00e0 11h30 HST<\/li>\n \t
        • Lieu : Kauai\/Maui (GS) room<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"

          Paris, France, le lundi, 4 mars 2024, 7h30 CET \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui que de nouvelles donn\u00e9es et analyses scientifiques relatives […]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[54],"tags":[],"featured-area":[],"news-topic":[73],"news-type":[75,77],"post-year":[],"class_list":["post-4193","post","type-post","status-publish","format-standard","hentry","category-communiques-de-presse-financiers","news-topic-gs010-lumevoq","news-type-clinical","news-type-conferences"],"acf":[],"yoast_head":"\nGenSight Biologics annonce des communications scientifiques sur LUMEVOQ\u00ae au Congr\u00e8s 2024 du NANOS - GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2024\/03\/04\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2024-du-nanos\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSight Biologics annonce des communications scientifiques sur LUMEVOQ\u00ae au Congr\u00e8s 2024 du NANOS - GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Paris, France, le lundi, 4 mars 2024, 7h30 CET \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui que de nouvelles donn\u00e9es et analyses scientifiques relatives […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2024\/03\/04\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2024-du-nanos\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-04T11:30:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-24T04:05:52+00:00\" \/>\n<meta name=\"author\" content=\"jbenedicto\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"jbenedicto\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/03\\\/04\\\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2024-du-nanos\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/03\\\/04\\\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2024-du-nanos\\\/\"},\"author\":{\"name\":\"jbenedicto\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"headline\":\"GenSight Biologics annonce des communications scientifiques sur LUMEVOQ\u00ae au Congr\u00e8s 2024 du NANOS\",\"datePublished\":\"2024-03-04T11:30:47+00:00\",\"dateModified\":\"2026-09-24T04:05:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/03\\\/04\\\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2024-du-nanos\\\/\"},\"wordCount\":399,\"articleSection\":[\"Communiqu\u00e9 de presse Financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/03\\\/04\\\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2024-du-nanos\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/03\\\/04\\\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2024-du-nanos\\\/\",\"name\":\"GenSight Biologics annonce des communications scientifiques sur LUMEVOQ\u00ae au Congr\u00e8s 2024 du NANOS - GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2024-03-04T11:30:47+00:00\",\"dateModified\":\"2026-09-24T04:05:52+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/03\\\/04\\\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2024-du-nanos\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/03\\\/04\\\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2024-du-nanos\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/03\\\/04\\\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2024-du-nanos\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSight Biologics annonce des communications scientifiques sur LUMEVOQ\u00ae au Congr\u00e8s 2024 du NANOS\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/2a44b94f44dbd4ddf0847f47b1768f1f\",\"name\":\"jbenedicto\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"caption\":\"jbenedicto\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenSight Biologics annonce des communications scientifiques sur LUMEVOQ\u00ae au Congr\u00e8s 2024 du NANOS - GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2024\/03\/04\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2024-du-nanos\/","og_locale":"fr_FR","og_type":"article","og_title":"GenSight Biologics annonce des communications scientifiques sur LUMEVOQ\u00ae au Congr\u00e8s 2024 du NANOS - GenSight Biologics","og_description":"Paris, France, le lundi, 4 mars 2024, 7h30 CET \u2013 GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce aujourd\u2019hui que de nouvelles donn\u00e9es et analyses scientifiques relatives […]","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2024\/03\/04\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2024-du-nanos\/","og_site_name":"GenSight Biologics","article_published_time":"2024-03-04T11:30:47+00:00","article_modified_time":"2026-09-24T04:05:52+00:00","author":"jbenedicto","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"jbenedicto","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2024\/03\/04\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2024-du-nanos\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2024\/03\/04\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2024-du-nanos\/"},"author":{"name":"jbenedicto","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"headline":"GenSight Biologics annonce des communications scientifiques sur LUMEVOQ\u00ae au Congr\u00e8s 2024 du NANOS","datePublished":"2024-03-04T11:30:47+00:00","dateModified":"2026-09-24T04:05:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2024\/03\/04\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2024-du-nanos\/"},"wordCount":399,"articleSection":["Communiqu\u00e9 de presse Financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2024\/03\/04\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2024-du-nanos\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2024\/03\/04\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2024-du-nanos\/","name":"GenSight Biologics annonce des communications scientifiques sur LUMEVOQ\u00ae au Congr\u00e8s 2024 du NANOS - GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2024-03-04T11:30:47+00:00","dateModified":"2026-09-24T04:05:52+00:00","author":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f"},"breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2024\/03\/04\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2024-du-nanos\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2024\/03\/04\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2024-du-nanos\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2024\/03\/04\/gensight-biologics-annonce-des-communications-scientifiques-sur-lumevoq-au-congres-2024-du-nanos\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"GenSight Biologics annonce des communications scientifiques sur LUMEVOQ\u00ae au Congr\u00e8s 2024 du NANOS"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/2a44b94f44dbd4ddf0847f47b1768f1f","name":"jbenedicto","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","caption":"jbenedicto"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/4193","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=4193"}],"version-history":[{"count":0,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/4193\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=4193"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=4193"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=4193"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=4193"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=4193"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=4193"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=4193"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}